Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study investigators are studying the effects of a drug called ketamine on the symptoms of Obsessive-compulsive disorder (OCD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

NCT02422290

Obsessive-Compulsive Disorder

COMPLETED PHASE1/PHASE2

Ketamine Infusion for Obsessive-Compulsive Disorder

NCT01349231

Obsessive-compulsive Disorder

COMPLETED PHASE2

Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)

NCT02062658

Obsessive-Compulsive Disorder

COMPLETED PHASE2

Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder

NCT01371110

Obsessive Compulsive Disorder

TERMINATED PHASE1/PHASE2

A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

NCT02234011

Obsessive-Compulsive Disorder

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Recent evidence suggest that a different neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD. In this study the investigators are recruiting patients to receive the drug ketamine, which is thought to modulate the neurotransmitter glutamate through the N-methyl-D-aspartate (NMDA), in a 2-week placebo controlled study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes

Group Type ACTIVE_COMPARATOR

Ketamine infusion

Intervention Type DRUG

0.5mg/kg IV over 40 minutes

Saline

Intervention Type OTHER

saline infusion

Group B

IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes

Group Type ACTIVE_COMPARATOR

Ketamine infusion

Intervention Type DRUG

0.5mg/kg IV over 40 minutes

Saline

Intervention Type OTHER

saline infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine infusion

0.5mg/kg IV over 40 minutes

Intervention Type DRUG

Saline

saline infusion

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ketamine hydrochloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-55
* Physically healthy and not currently pregnant
* Primary Diagnosis of OCD
* Sufficient severity of symptoms
* Able to provide consent

Exclusion Criteria

* Psychiatric conditions that make participation unsafe
* Currently on psychotropic medication
* Medical conditions that make participation unsafe
* Allergy to ketamine
* Any metal in the body

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No